Clinical considerations for ATTR-CM treatment timing with a TTR stabiliser

28 August 2026 (10:00 - 10:45)

Organised by:

About the speakers

Doctor Prem Soman

Upmc University Of Pittsburgh Medical Center, Pittsburgh (United States of America)

Doctor Nicole Cyrille-Superville

Charlotte (United States of America)

4 More presentations in this session

Presentation thumbnail

Opening address and introduction to ATTR-CM

Associate Professor R. Pfister (Cologne, DE)

Presentation thumbnail

Importance of timely detection of ATTR-CM

Doctor M. Hanna (Cleveland, US)

Presentation thumbnail

Emerging artificial intelligence approaches to ATTR-CM screening

Doctor R. Khera (New Haven, US) Professor C. Lam (Singapore, SG)

Presentation thumbnail

Time matters in ATTR-CM: emerging artificial intelligence approaches to screening and clinical considerations for treatment timing - discussion and closing

Access the full session

Session thumbnail

Time matters in transthyretin amyloid cardiomyopathy (ATTR-CM): emerging artificial intelligence approaches to screening and clinical considerations for treatment timing

The Event

Event poster

ESC Congress 2026

28 August 2026 10:00 CET

You may be interested in

Congress Session

ATTRibutes of change: advances in treating and monitoring ATTR-CM

17 May 2025

Congress Presentation

Evolving the understanding of TTR's role in health and disease

31 August 2025

Congress Presentation

When to stop? Real-world decision pathways for transthyretin stabilizer discontinuation in cardiac amyloidosis

31 August 2025

Congress Session

Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond

20 May 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources